Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Jim Tananbaum
AddedMar 31, 2024
UpdatedMay 31, 2026
Jim Tananbaum

Jim Tananbaum

Board Member, Fulcrum Therapeutics

Crunchbase

Jim Tananbaum's Career

Fulcrum Therapeutics
Fulcrum Therapeutics

Cambridge, MA, US

Board Member· Board
Cogentus Pharmaceuticals
Cogentus Pharmaceuticals

Menlo Park, CA, US

Board Member· Board
Roxro Pharma
Roxro Pharma

Menlo Park, CA, US

Board Member· Board
Tarsa Therapeutics
Tarsa Therapeutics

Philadelphia, PA, US

Board Member· Board
Pathwork Diagnostics
Pathwork Diagnostics

Redwood City, CA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Jim Tananbaum's Career

Fulcrum Therapeutics
Fulcrum Therapeutics
Public$603.3M892016Cambridge, MA, US
Board Member· Board

Leadership at Fulcrum Therapeutics

Mark LevinMark LevinBoard Member
James GeraghtyJames GeraghtyBoard Member
Jeannie T. LeeJeannie T. LeeFounder
Robert GouldRobert GouldBoard Member
Katina DortonKatina DortonBoard Member
Kate HavilandKate HavilandBoard Member

Similar to Fulcrum Therapeutics

Fulcrum PharmaceuticalsFulcrum PharmaceuticalsHenderson, NV, USDrug Developmentest. 2002Fulcrum PharmaceuticalsHenderson, NV, US · est. 2002

Fulcrum Pharmaceuticals: Innovating drug development through computational chemistry and biology since 2002.

Series A · $8M6
Astria TherapeuticsAstria TherapeuticsBoston, MA, USBiopharmaceuticalsest. 2008Astria TherapeuticsBoston, MA, US · est. 2008

Astria Therapeutics, Inc.: A clinical-stage biopharmaceutical company developing treatments for rare diseases and lipid disorders.

Public · $656.4M24
CAMP4 TherapeuticsCAMP4 TherapeuticsCambridge, MA, USTherapeuticsest. 2016CAMP4 TherapeuticsCambridge, MA, US · est. 2016

CAMP4 Therapeutics: A Massachusetts-based biotech firm specializing in disease treatment therapies.

Series B · $190M84
Triplet TherapeuticsTriplet TherapeuticsCambridge, MA, USBiotechnologyest. 2019Triplet TherapeuticsCambridge, MA, US · est. 2019

Triplet Therapeutics: Pioneering biotech firm developing transformative treatments for genetic diseases.

Series A · $59M36
Cogentus Pharmaceuticals
Cogentus Pharmaceuticals
Public$77.5M302006Menlo Park, CA, US
Board Member· Board

Leadership at Cogentus Pharmaceuticals

Mark A. GoldsmithMark A. GoldsmithCEO
Robert M MyersRobert M MyersBoard Member

Similar to Cogentus Pharmaceuticals

Coeptis PharmaceuticalsCoeptis PharmaceuticalsWexford, PA, USGenerics, Pharmaceuticalsest. 2018Coeptis PharmaceuticalsWexford, PA, US · est. 2018

Coeptis Pharmaceuticals: Developing and marketing high-quality branded and generic drugs globally.

Public · $1.5M30
Cogent BiosciencesCogent BiosciencesWaltham, MA, USBiotech, Therapiesest. 2014Cogent BiosciencesWaltham, MA, US · est. 2014

US-based Cogent Biosciences develops biotech solutions for genetically driven diseases.

Public · $692.7M138
Corcept TherapeuticsCorcept TherapeuticsMenlo Park, CA, USPharmaceuticalsest. 1998Corcept TherapeuticsMenlo Park, CA, US · est. 1998

Corcept Therapeutics Inc.: An American pharmaceutical company specializing in drugs for severe metabolic, psychiatric, and oncologic disorders.

Public · $80.1M299
Concours PharmaceuticalsConcours PharmaceuticalsTrenton, NJ, USPharmaceuticalsest. 2018Concours PharmaceuticalsTrenton, NJ, US · est. 2018

Concours Pharmaceuticals: Innovating oral drug delivery for advanced pharmaceutical development.

Seed · $2.7M30
Roxro Pharma
Roxro Pharma
Series B$68.8M21999Menlo Park, CA, US
Board Member· Board

Leadership at Roxro Pharma

Roberto RosenkranzRoberto RosenkranzBoard Member
Tarsa Therapeutics
Tarsa Therapeutics
Acquired$124.3M02009Philadelphia, PA, US
Board Member· Board

Leadership at Tarsa Therapeutics

Martin EdwardsMartin EdwardsBoard Member
Richard S. KollenderRichard S. KollenderBoard Member
Matt RiekeMatt RiekeBoard Member
Eric BednarskiEric BednarskiBoard Member
David BrandDavid BrandBoard Member
James GilliganJames GilliganCo-Founder
Pathwork Diagnostics
Pathwork Diagnostics
Acquired$63.5M02002Redwood City, CA, US
Board Member· Board

Leadership at Pathwork Diagnostics

Ken HaasKen HaasBoard Member
Peter KlemmPeter KlemmBoard Member
Richard KlausnerRichard KlausnerFounder
Greg LahannGreg LahannBoard Member
MOHAMMED SHAHZAD AHMED MALIKMOHAMMED SHAHZAD AHMED MALIKBoard Member
Richard BastianiRichard BastianiBoard Member

Similar to Pathwork Diagnostics

NanopathNanopathCambridge, MA, USDiagnostics, Womens Healthest. 2019NanopathCambridge, MA, US · est. 2019

Nanopath: A molecular diagnostics firm revolutionizing testing for women's health in a single visit.

Series A · $10.3M30
OncocyteOncocyteIrvine, CA, USCancer Diagnosticsest. 2009OncocyteIrvine, CA, US · est. 2009

Oncocyte Corporation: A US-based molecular diagnostics firm, optimizing cancer care through accelerated diagnosis and treatment.

Public · $57.2M75
PrecipioPrecipioNew Haven, CT, USCancer Diagnosticsest. 2011PrecipioNew Haven, CT, US · est. 2011

Precipio: A leading cancer diagnostics lab, providing expert advice for optimal patient care.

Public · $3.3M68

Jim Tananbaum's Similar Executives & Operators

Lau Eng BoonLau Eng BoonBoard Member · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance RetailMason YeoMason YeoBoard Member · KakaoJaeHong ChoiJaeHong ChoiBoard Member · KakaoSean JohSean JohBoard Member · Kakao

People Similar to Jim Tananbaum

JAMES BRUCE TANANBAUMJAMES BRUCE TANANBAUMFounder · Foresite CapitalDavid FontainDavid FontainCo-Founder & CEO · ForesightBernard FairmanBernard FairmanBoard Member · Foresight GroupCindy XiongCindy XiongBoard Member · Immpact BioJim BraileanJim BraileanCo-Founder · Karmel Capital